Mpro Inhibitor Screening With Amyloid–Gold Nanocomposites
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for screening Mpro inhibitors are inefficient due to high concentrations of Mpro required and lengthy screening times, and there is a need for a method that can effectively identify coronavirus therapeutic agents despite mutations in the spiked protein.
Innovation Solution
A method involving the preparation of an engineered amyloid nanocomposite composed of a specific amyloid peptide and gold nanoparticles, which changes color in response to Mpro activity, allowing rapid screening of Mpro inhibitors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional methods use high concentration of Mpro for screening, then the screening reliability is improved, but the cost increases and the screening time extends to several days
Solution Approach 1:
The invention changes the concentration parameter of Mpro from high to low (1-10 nM range), and simultaneously changes the detection method parameter from conventional fluorescence to colorimetric detection using gold nanoparticles. This parameter transformation enables rapid screening (within hours) while maintaining reliability through the high sensitivity of gold nanoparticle color changes
Solution Approach 2:
The invention replaces the conventional fluorescence-based detection system with a colorimetric system using gold nanoparticles. This substitution eliminates the need for expensive fluorescence equipment and enables simple visual or spectral detection, significantly reducing screening time and cost while maintaining detection reliability
2Reliability
If conventional methods use high concentration of Mpro for screening, then the screening reliability is improved, but the cost increases due to high unit price of Mpro
Solution Approach 1:
The invention transforms the Mpro concentration parameter from high (conventional levels) to low (1-10 nM), directly reducing the quantity of expensive Mpro required. The reliability is maintained through optimization of the gold nanoparticle detection system which provides high sensitivity even at low enzyme concentrations
Solution Approach 2:
The invention replaces expensive conventional detection reagents with inexpensive gold nanoparticles that provide stable, long-lasting colorimetric signals. The gold nanoparticles serve as a cost-effective alternative to expensive fluorescence substrates and specialized detection reagents
3Measurement precision
If conventional methods require two or more fluorescent substances for screening, then the measurement precision is improved, but the device complexity increases
Solution Approach 1:
The invention extracts and eliminates the need for multiple fluorescent substances and complex fluorescence detection equipment. By using gold nanoparticles with inherent colorimetric properties, the system achieves precise measurement with a single detection reagent and simple equipment, reducing device complexity while maintaining precision
Solution Approach 2:
The invention utilizes the color change property of gold nanoparticles (from red to blue/purple) as a direct visual and spectral indicator of Mpro activity. This colorimetric approach replaces complex fluorescence measurements with simple color detection, reducing device complexity while maintaining measurement precision through easily observable and quantifiable color changes
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method enables rapid and selective screening of Mpro inhibitors using a low concentration of Mpro, reducing screening time and enhancing efficiency.
Implementation Method 1
engineered amyloid nanocomposite... which changes color in response to Mpro activity
Implementation Method 2
preparing gold nanoparticles by mixing hydrogen tetrachloroaurate (HAuCl4) and sodium citrate
Data Source
AI summary
The present disclosure relates to a method for screening drugs for treating multiple-variant coronavirus disease. The present disclosure provides a method for screening coronavirus therapeutic agents in a short period of time by using a low concentration of Mpro.